Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Inovio Pharma (INO)

Inovio Pharma (INO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 107,435
  • Shares Outstanding, K 66,730
  • Annual Sales, $ 220 K
  • Annual Income, $ -107,250 K
  • EBIT $ -96 M
  • EBITDA $ -93 M
  • 60-Month Beta 1.72
  • Price/Sales 344.34
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 186.25% (-82.23%)
  • Historical Volatility 52.33%
  • IV Percentile 41%
  • IV Rank 14.29%
  • IV High 908.26% on 08/07/25
  • IV Low 65.86% on 05/05/25
  • Expected Move (DTE 6) 0.1530 (9.50%)
  • Put/Call Vol Ratio 0.01
  • Today's Volume 566
  • Volume Avg (30-Day) 790
  • Put/Call OI Ratio 0.04
  • Today's Open Interest 33,288
  • Open Int (30-Day) 26,862
  • Expected Range 1.4570 to 1.7630

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.37
  • Number of Estimates 3
  • High Estimate -0.36
  • Low Estimate -0.38
  • Prior Year -0.69
  • Growth Rate Est. (year over year) +46.38%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.4700 +9.52%
on 01/20/26
1.7800 -9.55%
on 02/03/26
+0.0100 (+0.62%)
since 01/13/26
3-Month
1.4700 +9.52%
on 01/20/26
2.7200 -40.81%
on 12/17/25
-0.3400 (-17.44%)
since 11/13/25
52-Week
1.3000 +23.85%
on 07/15/25
2.9789 -45.95%
on 09/09/25
-0.5200 (-24.41%)
since 02/13/25

Most Recent Stories

More News
Law Offices of Howard G. Smith Encourages Inovio Pharmaceuticals, Inc. (INO) Shareholders To Inquire About Securities Fraud Class Action

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Inovio Pharmaceuticals, Inc. (“Inovio” or the “Company”) (NASDAQ: ...

INO : 1.6100 (+1.90%)
Pomerantz Law Firm Announces the Filing of a Class Action Against Inovio Pharmaceuticals, Inc. and Certain Officers - INO

NEW YORK , Feb. 12, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Inovio Pharmaceuticals, Inc. ("Inovio" or the "Company") (NASDAQ: INO) and certain...

INO : 1.6100 (+1.90%)
Securities Fraud Investigation Into Inovio Pharmaceuticals, Inc. (INO) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

Glancy Prongay Wolke & Rotter LLP , a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Inovio Pharmaceuticals, Inc. (“Inovio”...

INO : 1.6100 (+1.90%)
Inovio Pharmaceuticals, Inc. (INO) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

Law Offices of Howard G. Smith announces an investigation on behalf of Inovio Pharmaceuticals, Inc. (“Inovio” or the “Company”) (NASDAQ: INO ) investors concerning the Company’s...

INO : 1.6100 (+1.90%)
Securities Fraud Investigation Into Inovio Pharmaceuticals, Inc. (INO) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

The Law Offices of Frank R. Cruz announces an investigation of Inovio Pharmaceuticals, Inc. (“Inovio” or the “Company”) (NASDAQ: INO ) on behalf of investors concerning the...

INO : 1.6100 (+1.90%)
INOVIO to Participate in Upcoming Scientific and Investor Conferences

PLYMOUTH MEETING, Pa. , Feb. 12, 2026 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated...

INO : 1.6100 (+1.90%)
Inovio Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – INO       

The DJS Law Group reminds investors of a class action lawsuit against Inovio Pharmaceuticals, Inc. (“Inovio” or “the Company”) (NASDAQ: INO ) for violations of §§10(b)...

INO : 1.6100 (+1.90%)
INO Investors Have Opportunity to Lead Inovio Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Inovio Pharmaceuticals, Inc. (“Inovio” or “the Company”) (NASDAQ:...

INO : 1.6100 (+1.90%)
INO SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Inovio Pharmaceuticals (INO) Investors of Securities Class Action Deadline on April 7, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Inovio To Contact Him Directly To Discuss Their Options

INO : 1.6100 (+1.90%)
IINO Stockholder Alert: Robbins LLP Reminds Investors of the Class Action Against Inovio Pharmaceuticals, Inc.

SAN DIEGO , Feb. 10, 2026 /PRNewswire/ -- Robbins LLP  reminds stockholders that a class action was filed on behalf of all persons that purchased or otherwise acquired Inovio Pharmaceuticals,...

INO : 1.6100 (+1.90%)

Business Summary

Inovio Pharmaceuticals, Inc., formerly known as Inovio Biomedical Corporation, is engaged in the discovery, development, and delivery of a new generation of vaccines, called DNA vaccines, focused on cancers and infectious diseases. The Company's electroporation DNA delivery technology uses brief, controlled...

See More

Key Turning Points

3rd Resistance Point 1.6883
2nd Resistance Point 1.6567
1st Resistance Point 1.6333
Last Price 1.6100
1st Support Level 1.5783
2nd Support Level 1.5467
3rd Support Level 1.5233

See More

52-Week High 2.9789
Fibonacci 61.8% 2.3376
Fibonacci 50% 2.1395
Fibonacci 38.2% 1.9413
Last Price 1.6100
52-Week Low 1.3000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar